Plain-English translation of NCT07449702 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a follow-up study for people who participated in an earlier trial of , a new treatment for moderate-to-severe plaque psoriasis. The study will watch how safe and how well the medication works over a longer period—about two years of treatment plus another year of follow-up after treatment ends. Researchers will track your skin, safety, and how your body responds to different dosing schedules.
While earlier trials showed promise, doctors need to understand how this medication performs over a longer time frame and whether different dosing schedules (once a year or twice a year) work better for different people. This information helps determine the best, safest way to use the treatment in real life.
You likely qualify if…
You likely don't qualify if…
If you join, you'll receive either once a year (at a higher or lower dose) or twice a year (every 6 months), or you may start with no medication until your skin improves to a certain level. You'll come for study visits over approximately 96 weeks (about two years) of treatment, then have follow-up visits for another 48 weeks after your last treatment. At each visit, your doctor will check how your skin is responding, monitor for any side effects, and run blood tests to make sure the treatment is safe for you.
AI-generated summary from trial data · Jul 5, 2026 · Not medical advice
United States